A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs TAK 041 (Primary)
  • Indications Cognition disorders
  • Focus Adverse reactions; First in man
  • Sponsors Takeda
  • Most Recent Events

    • 28 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
    • 28 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 11 Oct 2016 Planned End Date changed from 1 Nov 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top